Collegium Pharmaceutical, Inc.COLLNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

defenseworld.net

Analyzing Collegium Pharmaceutical (NASDAQ:COLL) and Pivotal Therapeutics (OTCMKTS:PVTTF)

Collegium Pharmaceutical (NASDAQ: COLL - Get Free Report) and Pivotal Therapeutics (OTCMKTS:PVTTF - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends. Risk and Volatility Collegium Pharmaceutical has a beta

defenseworld.net

Collegium Pharmaceutical, Inc. $COLL Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC reduced its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 23.6% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 639,694 shares of the specialty pharmaceutical company's stock after selling 197,855 shares during the

seekingalpha.com

Collegium Pharmaceutical: Buying The Projected Growth For 2026

Collegium Pharmaceutical demonstrates strong profitability, upgraded 2026 guidance, and a robust balance sheet, reinforcing my bullish outlook and conviction upgrade. COLL's growth is shifting from Xtampza ER to Jornay PM, which is expected to drive $190M–$200M in 2025 revenue and deeper ADHD market penetration. The pain portfolio remains a stable cash generator, with authorized generics providing a smart revenue stream and mitigating immediate generic erosion risks.

defenseworld.net

SG Americas Securities LLC Raises Position in Collegium Pharmaceutical, Inc. $COLL

SG Americas Securities LLC grew its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 215.6% during the third quarter, according to its most recent filing with the SEC. The firm owned 28,978 shares of the specialty pharmaceutical company's stock after acquiring an additional 19,796 shares during the period. SG Americas Securities

globenewswire.com

Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference

STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product, Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older and developed using a novel delayed-release extended-release delivery platform, at the American Professional Society of ADHD and Related Disorders (APSARD) Annual Conference being held from January 15-18, 2026, in San Diego, California.

fool.com

Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025

On Dec. 8, 2025, the Executive Vice President and Chief Commercial Officer of Collegium Pharmaceutical sold 17,600 shares directly through an exercise of options. The sale represented 14.5% of Dreyer's direct holdings at the time, reducing his direct ownership to 103,613 shares.

zacks.com

Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

globenewswire.com

Collegium Provides 2026 Financial Guidance and Business Update

– Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM ® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million – STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced its 2026 full-year financial guidance and provided a business update.

globenewswire.com

Collegium Announces the Closing of $980 Million Syndicated Credit Facility

STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility.

defenseworld.net

Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 12-Month High – Here’s What Happened

Shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL - Get Free Report) reached a new 52-week high on Friday. The stock traded as high as $50.00 and last traded at $49.9750, with a volume of 203913 shares. The stock had previously closed at $49.58. Analyst Ratings Changes Several research firms have commented on COLL. Barclays initiated

zacks.com

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

defenseworld.net

Assenagon Asset Management S.A. Purchases 92,898 Shares of Collegium Pharmaceutical, Inc. $COLL

Assenagon Asset Management S.A. raised its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 90.5% during the third quarter, according to its most recent filing with the SEC. The firm owned 195,589 shares of the specialty pharmaceutical company's stock after purchasing an additional 92,898 shares during the period. Assenagon Asset Management

zacks.com

Best Value Stocks to Buy for Dec. 18

KE, COLL and JRVR made it to the Zacks Rank #1 (Strong Buy) value stocks list on Dec. 18, 2025.

zacks.com

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

zacks.com

Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run?

Collegium Pharmaceutical (COLL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

defenseworld.net

Ensign Peak Advisors Inc Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL

Ensign Peak Advisors Inc cut its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 18.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,793 shares of the specialty pharmaceutical company's stock after selling 4,150 shares during the

defenseworld.net

Ballast Asset Management LP Makes New Investment in Collegium Pharmaceutical, Inc. $COLL

Ballast Asset Management LP bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 87,206 shares of the specialty pharmaceutical company's stock, valued at approximately $2,579,000. Ballast Asset Management LP owned

defenseworld.net

Collegium Pharmaceutical, Inc. $COLL Shares Sold by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP decreased its stake in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 18.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,531 shares of the specialty pharmaceutical company's stock after selling 3,630 shares during the quarter. Advantage Alpha Capital

zacks.com

Why 2025 is a Dynamic and Transformative Year for Collegium

COLL's bold buybacks, board refresh and expanding ADHD push highlight a year of strategic moves and rising momentum.

defenseworld.net

Bank of New York Mellon Corp Grows Stake in Collegium Pharmaceutical, Inc. $COLL

Bank of New York Mellon Corp increased its holdings in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 3.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 249,875 shares of the specialty pharmaceutical company's stock after buying an additional 7,614 shares

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance